ストックスクリーナーアプリを入手
2.23
1.83%
0.04
アフターアワーズ：
2.20
-0.03
-1.35%
Outlook Therapeutics Inc (OTLK) 最新ニュース
Outlook Therapeutics’ (OTLK) “Buy” Rating Reiterated at HC Wainwright - Defense World
Outlook Therapeutics (NASDAQ:OTLK) Earns Buy Rating from Guggenheim - MarketBeat
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Outlook Therapeutics (NASDAQ:OTLK) Receives Buy Rating from HC Wainwright - MarketBeat
Short Interest in Outlook Therapeutics, Inc. (NASDAQ:OTLK) Drops By 17.7% - MarketBeat
Outlook Therapeutics' (OTLK) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug - Benzinga
Outlook falls 10% on ONS-5010 update, warrant inducements - MSN
Outlook Therapeutics, Inc. Announces Complete Twelve Week Efficacy and Safety Results of Northeast EIGHT Clinical Trial - Marketscreener.com
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial - GlobeNewswire
Outlook Therapeutics' ONS-5010 Matches Ranibizumab in 12-Week AMD Trial Results - StockTitan
Analysts Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) Price Target at $32.73 - Defense World
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Outlook Therapeutics Reports 2024 Financial Results - MSN
Barclays PLC Increases Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Geode Capital Management LLC Raises Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
OTLKOutlook Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Outlook Therapeutics® Participates in Virtual Investor "What This Means” Segment - The Manila Times
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
Outlook's LYTENAVA Makes History: First Approved Ophthalmic Bevacizumab for Wet AMD in UK - StockTitan
Spartan Delta Corp (SDE-T) QuotePress Release - The Globe and Mail
Outlook Therapeutics (NASDAQ:OTLK) versus Candel Therapeutics (NASDAQ:CADL) Financial Survey - Defense World
State Street Corp Buys 21,201 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Analysts Offer Predictions for OTLK Q1 Earnings - Defense World
OTLK FY2026 EPS Lifted by Brookline Capital Management - Defense World
Age-related Vision Dysfunction Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight - The Globe and Mail
Biotech Alert: Searches spiking for these stocks today - TipRanks
Outlook Therapeutics Stock Surges on Positive Outlook Despite Lo - GuruFocus.com
Outlook Therapeutics Stock Surges on Positive Outlook Despite Loss - Yahoo Finance
Outlook Therapeutics Faces Business Risks from Third-Party Manufacturing Dependencies - MSN
Outlook Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - Marketscreener.com
Outlook Therapeutics provides ONS-5010/LYTENAVA update - Yahoo Finance
Outlook Therapeutics Inc. (OTLK) reports earnings - Quartz
Outlook Therapeutics Shares Up, Outlines Plans for Macular Degeneration Treatment - Marketscreener.com
Outlook Therapeutics Inc Reports Fiscal Year 2024 EPS of -$4.06, Missing Revenue Estimate of $0.24 Million - GuruFocus.com
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update - The Manila Times
Outlook Therapeutics Secures EU Approval for LYTENAVA™, First Bevacizumab Eye Treatment for Wet AMD - StockTitan
Brokerages Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) PT at $42.34 - Defense World
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutic - GuruFocus.com
Charles Schwab Investment Management Inc. Grows Stock Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Outlook Therapeutics : Reorganization Form 8 K - Marketscreener.com
Outlook Therapeutics® Streamlines Operations - The Manila Times
Outlook Therapeutics, Inc. Streamlines Operations - Marketscreener.com
Outlook Therapeutics to Cut 23% of Workforce in Push for Lytenava Commercial Launch - MarketWatch
After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright - Yahoo Finance
Outlook nabs NICE nod in wet AMD - The Pharma Letter
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD - The Manila Times
Outlook Therapeutics® Announces NICE Recommendation of - GlobeNewswire
Outlook Therapeutics' LYTENAVA Secures Groundbreaking NICE Recommendation for Wet AMD Treatment | OTLKW Stock News - StockTitan
0.65%
4.62%
大文字化:
|
ボリューム (24 時間):